INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA® Is a Personalized Immune Cell Therapy That Targets BCMA With a One-Time Infusion1*

MOA Video Thumbnail

Watch MOA video

Antigen-specific activation of ABECMA results in CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.1

ABECMA® CAR T Cell Diagram

ABECMA consists of T cells reengineered to express a CAR that contains:

ABECMA® CAR T Cell Diagram
  • 1An extracellular scFv-targeting domain that binds specifically to BCMA, a cell-surface antigen expressed at significantly higher levels on malignant plasma cells of MM1,2
  • 2A CD8α hinge that provides stability for CAR T cell expression and flexibility to access the targeted antigen1,3
  • 3A 4-1BB costimulatory domain, which is associated with enhanced CAR T cell activation, expansion, and persistence1,4
  • 4A CD3ζ signaling domain, which leads to CAR-positive T cell activation in response to binding of BCMA-expressing target cells1

BCMA is expressed both on normal and malignant plasma cells.

BCMA Icon

TARGETING BCMA


BCMA expression is largely restricted to plasma cells and is uniquely overexpressed on myeloma cells, making BCMA a promising target antigen.1,2

Learn more about ABECMA®
efficacy & safety

Find a certified
treatment center near you

Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 460 x 106 CAR-positive T cells in one or more infusion bags.

BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; MM=multiple myeloma; MOA=mechanism of action; RRMM=relapsed/refractory multiple myeloma; scFv=single-chain variable fragment.